ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations - Episode 8

Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies

November 5, 2024

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center, Christine Bestvina, MD, University of Chicago, Hatim Husain, MD, Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center, Julia K. Rotow, MD

This episode examines the management of ILD/pneumonitis associated with TROP2-directed ADCs in patients with advanced NSCLC and strategies for mitigating these risks, addresses hematologic toxicities related to docetaxel, and discusses the improved tolerability and lower incidence of severe treatment-emergent adverse events with Dato-DXd compared with docetaxel.

EP. 1: Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

EP. 2: Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA

EP. 3: ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC

EP. 4: Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations

EP. 5: Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC

EP. 6: Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

EP. 7: Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01

Now Viewing

EP. 8: Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies

Video content above is prompted by the following:

Have you observed ILD/pneumonitis associated with a TROP2-directed ADC among your patients with progressive, later-stage, or metastatic NSCLC either in practice or in the context of a clinical trial?
In your opinion, what are the most effective mitigation or prevention strategies that you follow to avoid precluding use of such therapy?
What has been your experience with docetaxel-related hematologic toxicities among patients with advanced or metastatic NSCLC? How do you manage these toxicities?
Are there laboratory threshold values that motivate you to interrupt, reduce, or discontinue dosing?
How encouraged are you by the lower overall incidence of grade greater than or equal to 3 treatment-emergent adverse events and improved tolerability with Dato-DXd vs docetaxel (25% vs 41%)? What is your experience with toxicity management of Dato-DXd?